Reports on a randomized controlled trial of HIV-infected men and women who, as a result of receiving selenium supplements, experienced lower HIV viral load and greater CD4 cell count.
Highlights NIDA-funded research to develop vaccines against addiction to drugs such as cocaine, nicotine, phencyclidine (PCP), and methamphetamine.
Highlights results from a pilot study suggesting that lofexidine, an anti-hypertensive medication, can enhance success rates among patients taking maintenance naltrexone to avoid opioid relapse.
Presents data on the length of stay in substance abuse treatment among people who were in treatment as a result of legal pressure as compared with those in treatment voluntarily.
Describes research with rats to better understand cocaine’s effect on the neural signaling in the learning circuits of the brain.
Reports on a study of men with co-occurring substance abuse and antisocial personality disorders and the potential benefit of judicially mandated addiction treatment.
Describes NIDA’s drug abuse and addiction research priorities for the use of the American Recovery and Reinvestment Act of 2009 funds.
Highlights a project in which nine research centers collaborate with criminal justice partners to test science-based tools for integrating drug abuse treatment in prisons and probation and parole programs.
Describes research revealing that for up to 6 weeks after smokers quit, their brain cells have more nicotine-binding receptors than nonsmokers, which may explain the struggle to quit.
Highlights NIDA-sponsored research underway to understand and respond to substance abusers’ needs at all points of care, from the initial presentation for treatment through recovery.